Latest Content

Revuforj Continues to Elicit Meaningful Responses in Some With Acute Leukemia

December 8th 2024, 6:22pm

By Kristie L. Kahl

Article

Long-term follow-data shows Revuforj to be effective in the treatment patients with R/R KMT2Ar acute leukemias.

D-VRd May Improve Minimal Residual Disease Responses in Multiple Myeloma

December 8th 2024, 5:36pm

By Kristie L. Kahl

Article

For patients with transplant-ineligible or -deferred newly diagnosed multiple myeloma, the addition of Darzalex to VRd improved MRD responses as well as progression-free survival.

Smoking May Be Linked With Genetic Mutations, Progression Risk in MDS

December 7th 2024, 7:28pm

By Darlene Dobkowski, MA

Article

Results from the study also showed the potential association between smoking, disease progression and survival in patients with myelodysplastic syndromes.

CAR-T Cell Therapy Shows EFS Benefit in Pediatric Leukemia Subset

December 7th 2024, 4:30pm

By Courtney Flaherty

Article

Treatment with bicistronic CD19/CD22 CAR-T cell therapy has shown event-free survival improvements in children with relapsed or refractory B-ALL.

Blincyto With Chemo May Improve Disease-Free Survival in Pediatric B-ALL

December 7th 2024, 3:04pm

By Ashling Wahner

Article

Pediatric patients with standard-risk B-ALL demonstrated significantly improved disease-free survival with Blincyto plus chemotherapy versus chemotherapy alone.

CURE Honors Seven Honorees at MPN Heroes Event

December 7th 2024, 1:51pm

By Darlene Dobkowski, MA

Article

CURE celebrated seven MPN Heroes, who ranged from patients to medical professionals, on the contributions they made in the community.

SBRT May Be Effective in Managing Intermediate-Risk Prostate Cancer

December 6th 2024, 10:00pm

By Ashley Chan

Article

Treatment with five-fraction SBRT could be effective versus traditional radiation in certain patients with low- or intermediate-risk prostate cancer.

The ABCs of ADCs in Breast Cancer

December 6th 2024, 8:00pm

By Debu Tripathy, M.D.

Article

Since 2000, antibody-drug conjugates have been approved by the Food and Drug Administration for various cancer types, such as breast cancer.

After Cancer, My Doctors Assume Everything I Have Is Cancer

December 6th 2024, 6:00pm

By Jessica Bolz

Article

When you’ve had cancer do doctors assume every ailment is cancer for you?

‘Rocky’ Series Star Dolph Lundgren is Cancer-Free, Boxer Israel Vazquez Died of Cancer and More

December 6th 2024, 4:00pm

By Alex Biese

Article

From a Hollywood star sharing an uplifting update to the death of a three-time boxing champion, here’s what’s happening in the cancer space this week.

MRIs May Predict Organ Preservation, Survival in Rectal Cancer

December 6th 2024, 2:00pm

By Spencer Feldman

Article

MRIs were able to predict organ preservation and survival with the “watch-and-wait” approach in patients with rectal cancer.

Lenvima Combo Misses End Goal in Children with Osteosarcoma

December 5th 2024, 10:00pm

By Spencer Feldman

Article

Combination therapy of Lenvima with Ipex and Vepesid misses end goal in children with osteosarcoma, but further research is needed.

Finding Hope With Antibody-Drug Conjugates in Managing Breast Cancer

December 5th 2024, 8:00pm

By Alex Biese

Article

With more than 150 treatments being studied in clinical trials, what is on the horizon for antibody-drug conjugates in breast cancer?

My Expectations of Follicular Lymphoma Treatment

December 5th 2024, 6:00pm

By Karen Cohn

Article

When I started receiving treatment for follicular lymphoma, I wasn’t sure what to expect regarding treatment — and a lot of things were unexpected.

‘Too Young For Cancer’ Author on the Importance of Advocating for Yourself

December 5th 2024, 4:00pm

By Alex Biese

Article

Author and kidney cancer survivor Katie Coleman explains why patients with cancer need to advocate for themselves when navigating the medical system.